Dr. Eric Nestler, scientific co-founder of PsychoGenics, is Chairman and Nash Family Professor of Neuroscience and Director of the Mount Sinai Brain Institute of the Mount Sinai School of Medicine, New York. He was formerly the Elizabeth Mears and House Jameson Professor of Psychiatry and Director of the Division of Molecular Psychiatry at Yale University School of Medicine and the McGinley Distinguished Professor and Chairman of the Department of Psychiatry at the University of Texas Southwestern Medical Center in Dallas. The focus of his research is molecular mechanisms underlying drug addiction and depression.
Dr. Fava is currently Executive Vice Chair for the MGH Department of Psychiatry, Executive Director, MGH Clinical Trials Network and Institute, and Director of the MGH Depression Clinical and Research Program, and Slater Family Professor of Psychiatry at Harvard Medical School. Under Dr. Fava’s direction, the MGH Depression Clinical and Research Program has become one of the most highly regarded depression programs in the country, conducting research projects in a variety of areas, including pharmacotherapy of resistant depression, neuroimaging, genetics, neurophysiology, neuroendocrinology, novel pharmacotherapies, alternative medicine, and psychotherapy.
Dr. Paul Greengard was awarded the Nobel Prize for Medicine and Physiology in 2000. He is the Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at Rockefeller University. Dr. Greengard is best known for work on the molecular and cellular mechanisms of signal transduction.
Dr. Lieberman is currently the Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, Director, New York State Psychiatric Institute, Psychiatrist-in-Chief, Columbia University Medical Center of the NewYork-Presbyterian Hospital. Dr. Lieberman's work has advanced the understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. He serves as PI on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) leading a multi-institution research team. He is the recipient of many national and international honors and awards; author of over 450 scientific articles; author or editor of twelve books.
Dr. McCall has over thirty years experience in the pharmaceutical industry including senior positions held at Pfizer, as Senior Vice President of Pfizer Global Research, Site Head for Pfizer Chicago, for Pharmacia and Upjohn as Vice President of Global Discovery Chemistry, Global Vice President Discovery Chemistry, and for Upjohn as Head of CNS and Head of Chemistry. Dr. McCall is currently the President of PharMac LLC, providing consulting services for drug discovery, project management, project evaluation, and research organization, to the pharmaceutical industry. He chairs the Spinal Muscular Atrophy project for NINDS and is a partner in the Apjohn Group.
Richard Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology at Columbia University in New York City. He is the director of the Gertrude H. Sergievsky Center, a center focused on epidemiological investigation of neurological diseases and the Co-Director of the Taub Institute for Research on Alzheimer disease and the Aging Brain. He is the current director of the National Institute on Aging Family Study of Alzheimer’s Disease. He has been the recipient of the 2007 Potamkin Prize, the 2008 John Stearns Award for Lifetime Achievement in Medicine and the 2009 Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research.
Dr. Steven Paul is the recently retired Executive Vice President and President of the Lilly Research Laboratories of Eli Lilly and Company. Prior to this position, Dr. Paul was Group Vice President of Discovery Research and Clinical Investigation as well as Vice President of Neuroscience Discovery Research at Lilly. In his role as Lilly’s R&D leader Dr. Paul oversaw the R&D efforts of over 8,000 scientists and physician investigators. Prior to assuming his position at Lilly, Dr. Paul served as the Scientific Director of the National Institute of Mental Health (NIH). Dr. Paul is a neuropsychopharmacologist and psychiatrist by training and his own research has focused on novel therapeutic interventions for Alzheimer’s disease, depression and schizophrenia. Among his many scientific contributions has been the delineation of the role for the inhibitory neurotransmitter GABA in mediating the behavioral effects of benzodiazepines, barbiturates, short-chain alcohols and a novel class of neuroactive steroids. Dr. Paul has published over 500 papers and invited book chapters and holds 8 patents on inventions made at Lilly and NIH and is an inventor of solanezumab one of Lilly’s late-stage drug candidates for Alzheimer’s disease.